Introduction {#S0001}
============

Upper tract urothelial carcinoma (UTUC) is relatively rare, with an approximate annual incidence of almost 2 cases per 100,000 individuals in Western countries, and accounts for only 5--10% of all urothelial carcinomas (UCs).[@CIT0001],[@CIT0002] Radical nephroureterectomy (RNU) with excision of the bladder cuff is the standard treatment for high-risk UTUCs,[@CIT0003],[@CIT0004] and kidney-sparing surgery can be the primary option for patients with low-risk tumors.[@CIT0001],[@CIT0005] Although the diagnosis and treatment for UTUC have significantly improved, the clinical outcome remains poor, as 5-year specific survival is less than 50% for patients with pT2/pT3 and less than 10% for patients with pT4.[@CIT0006]--[@CIT0008] Therefore, it is necessary to identify biomarkers that have the potential to predict prognosis and individualize adjuvant therapy based on the stratification of risks.

There is accumulating evidence that the preoperative immune-nutritional status plays crucial roles in human cancer development and progression.[@CIT0009],[@CIT0010] Recently, several biomarkers, such as serum sodium, hemoglobin, C-reactive protein (CRP), albumin, albumin to globulin ratio (AGR), plasma fibrinogen, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR), body mass index (BMI), sarcopenia and prognostic nutritional index (PNI), have been reported to be independent prognostic factors in many human malignancies, including UTUC.[@CIT0011],[@CIT0012]

The controlling nutritional status (CONUT) score, a new index calculated from three peripheral blood parameters (total lymphocyte count \[TLC\], serum albumin concentration and total cholesterol concentration \[TCC\]), was originally reported as an early screening tool to detect a poor nutritional status in 2005 ([Table 1](#T0001){ref-type="table"}).[@CIT0013] The CONUT score was proposed as a comprehensive index that could assess the immune response status and long-term nutritional effect of the host. Recently, the prognostic value of the preoperative CONUT score has been reported in many types of malignancies, such as colorectal cancer, esophageal cancer, gastric cancer, and renal cell carcinoma.[@CIT0014]--[@CIT0017] However, there are few studies on UTUC. Shihara and Xu reported that the CONUT score is an independent prognostic factor in UTUC patients treated with surgery.[@CIT0018],[@CIT0019] However, their studies were limited by the presence of selection bias, a short follow-up interval, a small sample size and limited covariates.

The aim of this study was to elucidate the prognostic value of the preoperative CONUT score in patients with localized UTUC treated with RNU using propensity score matching (PSM) analysis based on a nationwide high-volume cohort in China.

Materials and Methods {#S0002}
=====================

Patient Enrollment and Evaluation {#S0002-S2001}
---------------------------------

After obtaining approval by the internal ethics review board of Peking University First Hospital (approval no. 2015\[977\]), we retrospectively collected the records of 908 consecutive patients with localized UTUC who received surgical treatment at Peking University First Hospital between 1999 and 2015. A total of 154 patients were excluded from this study because of accompanying colorectal cancer, breast cancer or other malignancies (n=16), receiving adjuvant chemotherapy (n=44), missing clinicopathological data or follow-up data (n=90), or hepatitis (n=4). Ultimately, 754 patients were enrolled ([Figure 1](#F0001){ref-type="fig"}). All patients were treated with standard RNU with bladder cuff resection without any preoperative treatment. Routine lymph node dissection was performed in selected patients with enlarged lymph nodes that were found intraoperatively or by preoperative imaging.Figure 1Workflow of this study.

The clinicopathological and follow-up data were collected from a database containing the comprehensive medical records of UTUC patients. Staging was assessed according to the 2002 Union for International Cancer Control (UICC) TNM classification guidelines. Patients were graded based on the World Health Organization (WHO) 1973 grading system. Blood samples were obtained and measured within one week before the operation as regular preoperative laboratory tests. Exposure to aristolochic acids (AAs) was defined as a history of long-term exposure (\>3 months) of intermittent intake of regular doses of AA-containing traditional Chinese medicine. All procedures performed in this study were in accordance with the 1964 Declaration of Helsinki and its later amendments, and written informed consent was obtained from all patients.

For patients who were followed at our institute, their follow-up regimen included cystoscopy every 3 months for the first 3 years. The cystoscopy interval was extended to 1 year thereafter. Chest X-ray, urine cytology, serum creatinine tests, and abdominal ultrasound or CT/MRI evaluation were performed at the same time. Overall survival (OS) was determined by a review of patient medical records or data obtained from the Chinese National Statistical Ofﬁce database. Cancer-specific survival (CSS) and disease-free survival (DFS) were determined at the last follow-up based on examination results.

As a study in a single center, bias is inevitable. Therefore, all patient variables were adjusted using 1:1 PSM analysis to minimize selection bias.

Statistical Analysis {#S0002-S2002}
--------------------

All statistical tests were performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) or SAS 9.4 (SAS institute Inc., USA), and statistical significance was set at p\<0.05. To determine the optimum cutoff value for the preoperative CONT score, the receiver operating characteristic (ROC) curve of the CONUT score for DFS was analyzed, and the cutoff value for the preoperative CONUT score was deﬁned by the maximum Youden index value. Patients with a preoperative CONUT score over the cutoff value were as assigned to the high CONUT score group, while the remaining patients (CONUT score less than the cutoff value) were assigned to the low CONUT score group.

Several preoperative characteristics, such as age, BMI, American Statistical Association (ASA) score and hydronephrosis, were notably different between the low and high CONUT score patient cohorts (all p\<0.1). These preoperative characteristics might have an important impact on the CONUT score. To minimize bias, we performed PSM. The propensity scores were evaluated by nonparsimonious multivariate logistic regression according to the preoperative characteristics. In total, 204 patients with a high CONUT score were matched to 204 patients with a low CONUT score at a ratio of 1:1 using the nearest-neighbor method of PSM with a caliber of 0.1 ([Figure 1](#F0001){ref-type="fig"}). After PSM, the differences in preoperative characteristics between the low and high CONUT score groups were acceptable ([Figure 2](#F0002){ref-type="fig"} and [Table 3](#T0003){ref-type="table"}).Table 1CONUT Score SystemParameterNoneLightModerateSevereSerum albumin, g/dl≥3.503.00--3.492.50--2.99\<2.50Score0246TLC,/mm^3^≥16001200-1599800-1199\<800Score0123TCC^\#^, mg/dl≥180140-179100-139\<100Score0123[^2]Table 2Associations Between CONUT^\#^ Score and Clinicopathological Characteristics of the Patients According to CONUT Score (CONUT Score\<3 are Low Group, Otherwise High Group) Before Propensity Score MatchingCharacteristicsEntire CohortLow CONUT ScoreHigh CONUT ScorepNo. of subjects754550204Preoperative characteristics Age, years67.01±10.4666.46±10.6168.49±9.900.018\* Age (≥69)386 (51.2%)270 (49.1%)116 (56.9%)0.058 Gender (male)342 (45.4%)240 (43.6%)102 (50.0%)0.119 BMI^\#^24.29±3.5724.51±3.5023.68±3.710.005\* BMI (≥24.19 kg/m^2^)350 (46.4%)271 (49.3%)79 (38.7%)0.010\* Diabetes146 (19.4%)106 (19.3%)40 (19.6%)0.918 Hypertension333 (44.2%)241 (43.8%)92 (45.1%)0.753 Coronary disease129 (17.1%)96 (17.5%)33 (16.2%)0.679 Bladder tumor history34 (4.5%)26 (4.7%)8 (3.9%)0.636 ASA^\#^ score (≥3)145 (19.2%)89 (16.2%)56 (27.5%)\<0.001\* Alcohol89 (11.8%)63 (11.5%)26 (12.7%)0.626 Tobacco136 (18.0%)98 (17.8%)38 (18.6%)0.797 Exposure of AA^\#^63 (8.4%)43 (7.8%)20 (9.8%)0.381 Hydronephrosis419 (55.6%)294 (53.5%)125 (61.3%)0.055 The largest tumor location (pelvis)339 (45.0%)239 (43.5%)100 (49.0%)0.172Postoperative characteristics Pathological T stage (T2-4)481 (63.8%)332 (60.4%)149 (73.0%)0.001\* Lymph node status (N1)49 (6.5%)36 (6.5%)13 (6.4%)0.932 Tumor grade (G3)318 (42.2%)222 (40.4%)96 (47.1%)0.098 LVI^\#^47 (6.2%)33 (6.0%)14 (6.9%)0.663 Multifocality160 (21.2%)123 (22.4%)37 (18.1%)0.207 The largest tumor size3.59±2.473.36±2.153.66±2.260.095 The largest tumor size (≥3 cm)304 (40.3%)219 (39.8%)85 (41.7%)0.646 Tumor architecture (sessile)154 (20.4%)104 (18.9%)50 (24.5%)0.090 Squamous differentiation77 (10.2%)47 (8.5%)30 (14.7%)0.013\* Sarcomatoid differentiation34 (4.5%)26 (4.7%)8 (3.9%)0.636 Glandular differentiation36 (4.8%)21 (3.8%)15 (7.4%)0.043\*[^3][^4] Table 3Associations Between CONUT^\#^ Score and Clinicopathological Characteristics of the Patients According to CONUT Score (CONUT Score\<3 are Low Group, Otherwise High Group) After Propensity Score MatchingCharacteristicsEntire CohortLow CONUT ScoreHigh CONUT ScorepNo. of subjects408204204Preoperative characteristics Age, years67.81±10.3967.12±10.8468.49±9.900.184 Age (≥69)224 (54.9%)108 (52.9%)116 (56.9%)0.426 Gender (male)182 (47.1%)80 (39.2%)102 (50.0%)0.058 BMI^\#^24.00±3.8224.31±3.9223.68±3.710.095 BMI (≥24.19 kg/m^2^)176 (43.1%)97 (44.6%)79 (38.7%)0.549 Diabetes81 (19.9%)41 (20.1%)40 (19.6%)0.901 Hypertension188 (44.2%)96 (47.1%)92 (45.1%)0.691 Coronary disease74 (18.1%)43 (21.1%)33 (16.2%)0.438 Bladder tumor history18 (4.4%)10 (4.9%)8 (3.9%)0.630 ASA^\#^ score (≥3)119 (29.2%)63 (30.9%)56 (27.5%)0.446 Alcohol47 (11.5%)21 (10.3%)26 (12.7%)0.438 Tobacco72 (17.6%)34 (16.7%)38 (18.6%)0.603 Exposure of AA^\#^42 (10.3%)22 (710.8%)20 (9.8%)0.745 Hydronephrosis249 (61.0%)124 (60.8%)125 (61.3%)0.919 The largest tumor location (pelvis)195 (47.8%)95 (46.6%)100 (49.0%)0.620Postoperative characteristics Pathological T stage (T2-4)267 (65.4%)118 (57.8%)149 (73.0%)0.001\* Lymph node status (N1)23 (5.6%)10 (4.9%)13 (6.4%)0.520 Tumor grade (G3)173 (42.4%)77 (37.7%)96 (47.1%)0.057 LVI^\#^27 (6.6%)13 (6.4%)14 (6.9%)0.842 Multifocality84 (20.6%)47 (23.0%)37 (18.1%)0.221 The largest tumor size3.54±2.303.41±2.343.66±2.260.262 The largest tumor size (≥3 cm)164 (40.2%)79 (38.7%)85 (41.7%)0.545 Tumor architecture (sessile)84 (20.6%)34 (16.7%)50 (24.5%)0.093 Squamous differentiation47 (11.5%)17 (8.3%)30 (14.7%)0.044\* Sarcomatoid differentiation20 (4.9%)12 (5.9%)8 (3.9%)0.359 Glandular differentiation23 (5.6%)8 (3.9%)15 (7.4%)0.133[^5][^6] Figure 2Line plot of individual differences (**A**) and dot-plot of standardized mean differences (**B**) in propensity score matching.

Pearson's test and the chi-square test were used to determine the distribution of categorical variables, and the Mann--Whitney *U*-test was used for continuous variables. OS, CSS and DFS curves were plotted using the Kaplan-Meier method and analyzed by the Log rank test. The univariate analysis was assessed by the Log rank test, and the multivariate analysis was evaluated using the Cox proportional hazard regression model. Only those variables that were identified as significant (p\<0.05) in the univariate analysis were included in the multivariate analysis. Sensitivity analyses were also used to measure the potential effect of an unmeasured confounder on the relationship between preoperative CONUT score and the oncological outcomes.

Results {#S0003}
=======

Patient Characteristics {#S0003-S2001}
-----------------------

Given that a CONUT score of 3 had a maximum Youden index value, the cutoff value for the CONUT score was set as 3 ([Figure 3](#F0003){ref-type="fig"}). Patients with a CONUT score ≥3 were assigned to the high CONUT score group, and those with a CONUT score\<3 were assigned to the low CONUT score group. Of the 754 UTUC patients, 204 (27.1%) had a high CONUT score. The patient clinicopathological characteristics before and after PSM are described in [Tables 2](#T0002){ref-type="table"} and [3](#T0003){ref-type="table"}, respectively. The median patient age was 69 years (interquartile range \[IQR\] 61--74 years), and the median follow-up duration was 61 months (IQR 45--105 months). Patients in the high CONUT score group were significantly older (p=0.018), had a lower BMI (p=0.005), had a high ASA score (p\<0.001) and were more likely to have hydronephrosis (p=0.055, 53.5% vs 61.3%). These patients were also more likely to have advanced pathological T stage (p=0.001), squamous differentiation (p=0.013) and glandular differentiation (p=0.043) compared with the low CONUT score group. These patients also tended to have an advanced cellular grade (≥G3, p=0.098, 40.4% vs 47.1%) and sessile tumors (p=0.090, 18.9% vs 24.5%) compared with the low CONUT score group.Figure 3ROC curves used to predict DFS according to the preoperative CONUT score (A-continuous, AUC = 0.563; B-stratified by cutoff=3, AUC = 0.548).**Abbreviations:** DFS, disease-free survival; ROC, receiver operating characteristic; CONUT, controlling nutritional status; AUC, area under the curve.

Survival Outcomes {#S0003-S2002}
-----------------

### Before PSM {#S0003-S2002-S3001}

After a median (IQR) of 32 (19--56) months postoperatively, 234 (31.0%) patients died from any cause. Postoperatively, 165 (21.5%) patients experienced cancer-specific mortality after a median (IQR) of 26 (16--44) months, and 362 (48.0%) patients experienced disease progression after a median (IQR) of 21 (11--39) months. The Kaplan-Meier curves showed signiﬁcantly poor OS (p=0.021), CSS (p=0.028), and DFS (p\<0.001) for patients with a high preoperative CONUT score ([Figure 4A](#F0004){ref-type="fig"}, [C](#F0004){ref-type="fig"} and [E](#F0004){ref-type="fig"}). A high preoperative CONUT score was found to be an independent risk factor for DFS (hazard ratio \[HR\] 1.418, 95% confidence interval \[CI\] 1.132--1.776, p=0.002) but not OS (HR 1.273, 95% CI 0.960--1.686, p=0.093) or CSS (HR 1.328, 95% CI 0.954--1.847, p=0.092) based on multivariate Cox regression analyses when adjusted for clinicopathological parameters, as shown in [Table 4](#T0004){ref-type="table"}. For OS, patient sex, hypertension, ASA score ≥3, pathological T and N stages, tumor size, and glandular differentiation were signiﬁcant co-predictors (all p\<0.05). Moreover, patient sex, hypertension, pathologic T and N stages, and tumor size were proved to be independent co-predictors of postoperative CSS and DFS (all p\<0.05). Tumor glandular differentiation (p=0.011) signiﬁcantly predicted DFS but not CSS ([Table 4](#T0004){ref-type="table"}).Table 4Univariate and Multivariate Analyses of the Relationship Between Preoperative CONUT^\#^ Score and Oncological Outcome in Patients with Localized UTUC Before Propensity Score MatchingCharacteristicsOverall SurvivalCancer-Specific SurvivalDisease-Free SurvivalUnivariate AnalysesMultivariate AnalysesUnivariate AnalysesMultivariate AnalysesUnivariate AnalysesMultivariate AnalysesHR^\#^ (95% CI^\#^), pHR (95% CI), pHR (95% CI), pHR (95% CI), pHR (95% CI), pHR (95% CI), pCONUT score (≥3)1.383 (1.048--1.824), 0.022\*1.273 (0.960--1.686), 0.0931.435 (1.036--1.988), 0.030\*1.328 (0.954--1.847), 0.0921.540 (1.234--1.922), \<0.001\*1.418 (1.132--1.776), 0.002\*Age (≥69)1.257 (0.972--1.627), 0.0821.205 (0.887--1.638), 0.2331.229 (0.999--1.512), 0.052Gender (male)1.550 (1.199--2.005), 0.001\*1.443 (1.113--1.872), 0.006\*1.799 (1.321--2.451), \<0.001\*1.637 (1.198--2.237), 0.002\*1.467 (1.193--1.804), \<0.001\*1.436 (1.165--1.771), 0.001\*BMI^\#^ (≥24.19 kg/m^2^)0.908 (0.702--1.175), 0.4640.751 (0.550--1.025), 0.0710.877 (0.713--1.079), 0.214Diabetes0.902 (0.646--1.259), 0.5440.907 (0.610--1.347), 0.6271.030 (0.794--1.338), 0.822Hypertension1.452 (1.123--1.878), 0.004\*1.371 (1.049--1.790), 0.021\*1.388 (1.022--1.884), 0.036\*1.433 (1.051--1.953), 0.023\*1.349 (1.095--1.661), 0.005\*1.337 (1.078--1.658), 0.008\*Coronary disease0.933 (0.742--1.173), 0.5520.787 (0.507--1.223), 0.2881.084 (0.825--1.423), 0.562Bladder tumor history0.529 (0.235--1.190), 0.1240.364 (0.116--1.142), 0.0831.093 (0.679--1.759), 0.715ASA^\#^ score (≥3)1.740 (1.311--2.310), \<0.001\*1.539 (1.146--2.067), 0.004\*1.419 (0.997--2.020), 0.0521.417 (1.113--1.804), 0.005\*1.271 (0.988--1.634), 0.062Alcohol1.163 (0.801--1.690), 0.4270.906 (0.555--1.478), 0.6921.000 (0.731--1.367), 1.000Tobacco1.300 (0.953--1.773), 0.0971.250 (0.860--1.815), 0.2421.058 (0.813--1.378), 0.674Exposure of AA^\#^0.458 (0.243--0.863), 0.016\*0.547 (0.289--1.037), 0.0650.314 (0.129--0.765), 0.011\*0.413 (0.169--1.010), 0.0521.211 (0.853--1.719), 0.285Hydronephrosis1.165 (0.899--1.512), 0.2481.274 (0.932--1.742), 0.1281.209 (0.981--1.491), 0.075Pathological T stage (T2-4)2.671 (1.929--3.698), \<0.001\*2.072 (1.455--2.951), \<0.001\*4.125 (2.633--6.463), \<0.001\*3.019 (1.867--4.882), \<0.001\*1.614 (1.282--2.032), \<0.001\*1.349 (1.049--1.734), 0.020\*Lymph node status (N1)2.474 (1.655--3.097), \<0.001\*2.029 (1.329--3.099), 0.001\*2.938 (1.890--4.567), \<0.001\*2.100 (1.309--3.371), 0.002\*1.839 (1.257--2.691), 0.002\*1.725 (1.167--2.551), 0.006\*Tumor grade (G3)1.611 (1.246--2.082), \<0.001\*1.028 (0.767--1.378), 0.8531.831 (1.347--2.489), 0.001\*1.010 (0.686--1.486), 0.9591.285 (1.044--1.581), 0.018\*0.979 (0.774--1.239), 0.860LVI^\#^1.114 (0.660--1.880), 0.6861.375 (0.780--2.424), 0.2701.122 (0.734--1.713), 0.596Multifocality1.044 (0.770--1.416), 0.7831.152 (0.806--1.645), 0.4371.015 (0.797--1.293), 0.905Tumor architecture (sessile)1.077 (0.955--1.214), 0.2262.012 (1.446--2.800), \<0.001\*1.258 (0.840--1.885), 0.2651.091 (0.988--1.206), 0.086The largest tumor size (≥3 cm)1.521 (1.177--1.966), 0.001\*1.314 (1.011--1.707), 0.041\*1.707 (1.258--2.317), 0.001\*1.411 (1.031--1.930), 0.031\*1.313 (1.066--1.616), 0.010\*1.253 (1.012--1.550), 0.039\*Squamous differentiation1.432 (0.958--2.142), 0.0801.508 (0.953--2.386), 0.0801.537 (1.101--2.148), 0.012\*1.342 (0.942--1.911), 0.103Sarcomatoid differentiation2.144 (1.308--3.514), 0.002\*1.284 (0.759--2.171), 0.3522.314 (1.313--4.078), 0.004\*1.207 (0.659--2.209), 0.5241.451 (0.891--2.364), 0.134Glandular differentiation2.408 (1.488--3.897), \<0.001\*2.026 (1.236--3.321), 0.005\*2.388 (1.354--4.210), 0.003\*1.743 (0.968--3.139), 0.0642.082 (1.351--3.207), 0.001\*1.789 (1.145--2.794), 0.011\*[^7][^8] Figure 4OS (**A**), CSS (**C**) and DFS (**E**) of the 754 patients with localized UTUC according to the preoperative CONUT score before propensity score matching; OS (**B**), CSS (**D**) and DFS (**F**) of the 408 patients with localized UTUC according to the preoperative CONUT score after propensity score matching.**Abbreviations:** OS, overall survival; CSS, cancer-specific survival; DFS, disease-free survival; UTUC: upper tract urothelial carcinoma; CONUT: controlling nutritional status.

### After PSM {#S0003-S2002-S3002}

After a median (IQR) of 30 (18--53) months postoperatively, 127 (31.1%) patients died from any cause. Preoperatively, 90 (22.1%) patients experienced cancer-specific mortality after a median (IQR) of 24 (15--41) months, and 213 (52.2%) patients experienced disease progression after a median (IQR) of 19 (10--39) months. The Kaplan-Meier curves showed signiﬁcantly inferior OS (p=0.017), CSS (p=0.020), and DFS (p=0.004) for patients with a high preoperative CONUT score ([Figure 4B](#F0004){ref-type="fig"}, [D](#F0004){ref-type="fig"} and [F](#F0004){ref-type="fig"}). Multivariate Cox regression analyses demonstrated that a high CONUT score was an independent risk factor for OS (HR 1.459, 95% CI 1.010--2.107, p=0.044) and DFS (HR 1.333, 95% CI 1.010--1.760, p=0.042) but not CSS (HR 1.336, 95% CI 0.863--2.067, p=0.194), as shown in [Table 5](#T0005){ref-type="table"}. For OS, patient sex, hypertension, ASA score ≥3, pathological T and N stages and glandular differentiation were signiﬁcant co-predictors. Moreover, patient sex, pathological N stage and tumor glandular differentiation were revealed as independent co-predictors of postoperative CSS and DFS (all p\<0.05). Pathological T stage (p\<0.001) signiﬁcantly predicted CSS but not DFS in the propensity score-matched cohort ([Table 5](#T0005){ref-type="table"}).Table 5Univariate and Multivariate Analyses of the Relationship Between Preoperative CONUT^\#^ Score and Oncological Outcome in Patients with Localized UTUC^\#^ After Propensity Score MatchingCharacteristicsOverall SurvivalCancer-Specific SurvivalDisease-Free SurvivalUnivariate AnalysesMultivariate AnalysesUnivariate AnalysesMultivariate AnalysesUnivariate AnalysesMultivariate AnalysesHR^\#^ (95% CI^\#^), pHR (95% CI), pHR (95% CI), pHR (95% CI), pHR (95% CI), pHR (95% CI), pCONUT score (≥3)1.530 (1.075--2.177), 0.018\*1.459 (1.010--2.107), 0.044\*1.644 (1.077--2.509), 0.021\*1.336 (0.863--2.067), 0.1941.479 (1.127--1.942), 0.005\*1.333 (1.010--1.760), 0.042\*Age (≥69)1.069 (0.754--1.518), 0.7071.080 (0.712--1.637), 0.7181.082 (0.825--1.420), 0.568Gender (male)1.771 (1.247--2.513), 0.001\*1.519 (1.049--2.198), 0.027\*2.233 (1.461--3.414), \<0.001\*2.057 (1.338--3.161), 0.001\*1.655 (1.263--2.169), \<0.001\*1.641 (1.246--2.163), \<0.001\*BMI^\#^ (≥24.19 kg/m^2^)0.882 (0.620--1.254), 0.4830.729 (0.476--1.116), 0.1450.775 (0.589--1.020), 0.069Diabetes0.887 (0.569--1.383), 0.5960.955 (0.570--1.602), 0.8630.958 (0.683--1.344), 0.804Hypertension1.148 (0.810--1.628), 0.4371.371 (1.049--1.790), 0.021\*1.058 (0.699--1.602), 0.7901.141 (0.868--1.499), 0.344Coronary disease0.896 (0.672--1.196), 0.4560.734 (0.431--1.250), 0.2550.991 (0.850--1.154), 0.905Bladder tumor history0.628 (0.232--1.700), 0.3600.217 (0.030--1.561), 0.1291.191 (0.667--2.145), 0.549ASA^\#^ score (≥3)1.821 (1.281--2.589), 0.001\*2.094 (1.459--3.005), \<0.001\*1.488 (0.972--2.279), 0.0681.304 (0.981--1.734), 0.067Alcohol1.511 (0.937--2.435), 0.0911.365 (0.758--2.456), 0.3001.246 (0.841--1.845), 0.273Tobacco1.552 (1.030--2.435), 0.036\*1.405 (0.904--2.184), 0.1311.605 (0.992--2.597), 0.0541.129 (0.799--1.595), 0.493Exposure of AA^\#^0.465 (0.217--0.998), 0.049\*0.566 (0.263--1.220), 0.1460.275 (0.087--0.869), 0.028\*0.350 (0.110--1.110), 0.0751.108 (0.723--1.698), 0.638Hydronephrosis0.943 (0.662--1.344), 0.7461.238 (0.801--1.913), 0.3361.075 (0.815--1.418), 0.608Pathological T stage (T2-4)2.647 (1.685--4.160), \<0.001\*2.093 (1.290--3.395), 0.003\*4.658 (2.413--8.991), \<0.001\*3.432 (1.727--6.820), \<0.001\*1.385 (1.027--1.866), 0.033\*1.128 (0.826--1.541), 0.448Lymph node status (N1)2.533 (1.395--4.599), 0.002\*2.450 (1.306--4.595), 0.005\*3.522 (1.915--6.480), \<0.001\*3.084 (1.601--5.941), 0.001\*2.117 (1.227--3.653), 0.007\*1.990 (1.139--3.478), 0.016\*Tumor grade (G3)1.462 (1.032--2.071), 0.033\*0.910 (0.601--1.377), 0.6551.850 (1.220--2.805), 0.004\*1.055 (0.656--1.695), 0.8261.260 (0.961--1.652), 0.095LVI\#0.866 (0.404--1.856), 0.7111.067 (0.466--2.444), 0.8781.020 (0.593--1.756), 0.942Multifocality1.226 (0.817--1.840), 0.3241.484 (0.935--2.356), 0.0941.191 (0.874--1.756), 0.269Tumor architecture (sessile)1.071 (0.880--1.304), 0.4931.083 (0.870--1.349), 0.4761.141 (1.006--1.294), 0.040\*1.112 (0.936--1.323), 0.227The largest tumor size (≥3 cm)1.521 (1.173--2.155), 0.018\*1.365 (0.955--1.951), 0.0871.695 (1.121--2.563), 0.012\*1.432 (0.939--2.182), 0.0951.180 0.898--1.552), 0.235Squamous differentiation1.740 (1.066--2.838), 0.027\*1.258 (0.743--2.130), 0.3941.747 (0.986--3.096), 0.0561.733 (1.161--2.585) 0.007\*1.394 (0.917--2.119), 0.121Sarcomatoid differentiation2.144 (1.308--4.331), 0.013\*1.514 (0.751--3.052), 0.2472.215 (1.023--4.796), 0.044\*1.223 (0.538--2.781), 0.6301.445 (0.765--2.730), 0.257Glandular differentiation2.346 (1.262--4.358), 0.007\*2.165 (1.113--4.211), 0.023\*2.698 (1.353--5.382), 0.005\*2.497 (1.192--5.230), 0.015\*2.112 (1.247--3.577), 0.005\*1.859 (1.074--3.219), 0.027\*[^9][^10]

Sensitivity analyses revealed that the relationship between preoperative CONUT score and the oncological outcomes was maintained (data not shown).

Discussion {#S0004}
==========

Based on patients with localized UTUC treated with RNU from a nationwide high-volume cohort in China, we found that a high preoperative CONUT score was significantly related to certain adverse clinical and pathological characteristics, and a high CONUT score was associated with poor oncological outcomes before and after PSM. These results suggest that a high preoperative CONUT score is a robust independent predictor for localized UTUC.

The optimum cutoff value of the CONUT score vary from study to study. In our study, it was 3 according to the ROC curve, which was in accordance with previous studies.[@CIT0019]--[@CIT0021] PSM analysis has been used in many studies to balance subgroups across selected factors.[@CIT0022] In our study, to balance the baseline characteristics of preoperative covariates between the two groups, we used the PSM method. The differences in preoperative covariates between the low and high CONUT score groups were acceptable.

Ideal cancer predictors should be objective, inexpensive, quickly measured, simple to use, and available before surgery. Similar to objective data assessment (ODA) and subjective global assessment (SGA), the CONUT score has been reported to be a simple and cost-effective method of comprehensively and objectively detecting and controlling hospital malnutrition.[@CIT0013] It is comprised of the TLC, serum albumin concentration and TCC, reflecting immune function, host protein metabolism, and lipid metabolism, respectively.[@CIT0013] Thus, the CONUT score reflects not only the host status of nutrition but also systemic inflammation and the immune response. The combination of these three parameters can conceal their individual weaknesses and emphasize the advantage of each parameter. The mechanism underlying the association between a high CONUT score and a poor prognosis in human cancer remains unclear. The prognostic value of the preoperative CONUT score in UTUC patients might be explained by the functions of these three parameters.

The TLC, an indicator of the immunological status,[@CIT0011] plays important roles in inhibiting tumor cell malignant phenotypes, such as cell proliferation, invasion, and migration, by initiating a cytotoxic immune response.[@CIT0010] The number of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment has a crucial impact on the prognosis and immunotherapy outcome of various human tumors.[@CIT0023],[@CIT0024] A previous study indicated that TILs might affect the host response to neoadjuvant chemotherapy in bladder cancer.[@CIT0023] The TLC in the peripheral blood may indicate the number of TILs. Several biomarkers based on the TLC, such as NLR and PLR, were proven to be indexes for the immune status and serve as prognostic predictors for UTUC.[@CIT0011],[@CIT0025],[@CIT0026]

As a reliable indicator of the status of host nutrition and systematic inflammation, serum albumin can be influenced not only by the production of proinflammatory cytokines,[@CIT0027] such as interleukin-6 and tumor necrosis factor-alpha, but also by body fluid retention and damage to hepatocytes.[@CIT0028],[@CIT0029] Previous studies revealed that hypoalbuminemia was associated with immune deficiency. Furthermore, hypoalbuminemia was demonstrated to be associated with poor outcomes in UTUC patients.[@CIT0030]

Finally, as an important component of human cell membranes, cholesterol plays an essential role in maintaining the membrane structure, ﬂuidity and membrane protein activity.[@CIT0031],[@CIT0032] Thus, hypocholesterolemia may affect the mobility of cell surface receptors and their value in transmitting transmembrane signals. Increasing evidence has revealed an inverse association between the TCC in the blood and cancer incidence and mortality.[@CIT0033],[@CIT0034] Abnormal lipid metabolism has been demonstrated to be closely related to cancer development. The increased mRNA expression of low-density lipoprotein (LDL) receptor was found in colorectal tumor tissue compared to normal tissue, resulting in a high intake of LDL, which increases tumor growth.[@CIT0035] A previous study revealed that chronic cholesterol depletion promoted tumor cell proliferation by inducing NFkB activation.[@CIT0036] Furthermore, hypocholesterolemia was shown to be associated with a poor prognosis in many cancer patients.[@CIT0037],[@CIT0038]

Previous studies indicated that nutritional intervention could reduce postoperative complications and improve the tolerance of patients to anticancer treatment.[@CIT0039],[@CIT0040] However, the effects of nutritional intervention on the long-term oncological outcomes in patients with cancer-related malnutrition have not been confirmed. Our results remind us of the importance of perioperative nutritional support in UTUC patients. In addition, immunotherapy is becoming a promising strategy for the management of UTUC. The CONUT score may be a useful index for the selection of patients who need perioperative nutritional intervention in UTUC treatment.

Although important discoveries were revealed, our study had certain limitations. First, it was a retrospective single-center and single-race study. Therefore, we matched the patient preoperative variables between the high and low CONUT score groups using PSM analysis, which made the differences in preoperative covariates between the two groups acceptable. However, further multicenter interracial prospective studies are needed to clarify the prognostic role of the preoperative CONUT score in UTUC patients. Second, the CONUT score might have been biased by medicine or the presence of undetected conditions that affect the TLC, serum albumin concentration or TCC. Third, we did not obtain information on the CONUT score or nutritional support after surgery, which might influence our results. Finally, the mechanism by which the CONUT score affects the survival of patients with UTUC should be further explored using basic studies. Despite these limitations, we revealed that the preoperative CONUT score was correlated with oncological outcome in patients with UTUC.

Conclusion {#S0005}
==========

Our study revealed that the preoperative CONUT score is a convenient and effective factor for predicting prognosis in patients with localized UTUC after RNU. Perioperative nutritional intervention should be emphasized in UTUC patients.
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